New JAMA study digs into the rise of stacking FDA’s expedited programs and designations for new drugs
The number of pharma sponsors taking advantage of the FDA’s expedited programs has skyrocketed in recent years, including the use of multiple designations to hurry …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
